Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The Glucagon-Like Peptide 1 (GLP) Receptor as a Therapeutic Target in Parkinsons Disease: Mechanisms of Action
A Game-Changer for Cardiovascular Risk and Mortality The SELECT trial showed a 1.5% absolute and a 20% relative risk reduction in cardiovascular death, non-fatal MI, and non-fatal stroke
A 30-week randomized non-inferiority study comparing 2 mg once-weekly EX-LAR with 10 g twice-daily EX in 295 patients with T2DM
By handling the intricate semaglutide prior authorization process on your behalf, Klinic eliminates the bureaucratic complexities so you can focus on your journey to health
MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia 130, Suppl 1, 2017
To contextualize the pharmacological profile of Dihexa, laboratory investigators frequently run comparative assays against other well-characterized neurogenic and neuroprotective compounds within the PX1 Research catalog
